- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05892341
AQUACEL® Ag+ Extra™ and Cutimed™ Sorbact® Dressing in the Management of Venous Leg Ulcers Over a 12-week Period
March 19, 2024 updated by: ConvaTec Inc.
A Clinical Study to Compare the Performance of AQUACEL® Ag+ Extra™ and Cutimed® Sorbact® Dressing in the Management of Patients With Venous Leg Ulcers Over a 12-week Period
Study is to provide evidence comparing AQUACEL® Ag+ Extra™ versus Cutimed® Sorbact® in the progression of wounds towards healing
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Post market, multi-centre, randomised, open label, multi-national, prospective study to provide evidence comparing AQUACEL® Ag+ Extra™ versus Cutimed® Sorbact® in the progression of wounds towards healing
Study Type
Interventional
Enrollment (Actual)
205
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Catarina Saavedra, MD
- Phone Number: 3173637942
- Email: info@clinicasesteticas.com.co
Study Contact Backup
- Name: Markus Stuecker, MD
- Email: info@klinikum-bochum.de
Study Locations
-
-
-
Barranquilla, Colombia
- Convatec Colombia Clinic
-
Bogotá, Colombia
- Convatec Colombia Clinic
-
Bucaramanga, Colombia
- Convatec Colombia Clinic
-
Cali, Colombia
- Convatec Colombia Clinic
-
Cartagena, Colombia
- Convatec Colombia Clinic
-
Medellín, Colombia
- Convatec Colombia Clinic
-
-
-
-
-
Augsburg, Germany
- Germany
-
Berlin, Germany
- Germany
-
Bochum, Germany
- Germany
-
Düsseldorf, Germany
- Germany
-
Holzkirchen, Germany
- Germany
-
Ingolstadt, Germany
- Germany
-
München, Germany
- Germany Clinic II
-
München, Germany
- Germany Clinic I
-
Nürnberg, Germany
- Germany
-
Ratzeburg, Germany
- Germany
-
Rosenheim, Germany
- Germany
-
-
-
-
-
Derby, United Kingdom
- VCTC UK
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Venous insufficiency as defined by CEAP Classification of C6
- One wound amendable to treatment with either AQUACEL® Ag+ Extra™ or Cutimed® Sorbact®
- Wounds that have been present for at least 2 months
- Reliable and available for follow-up
- 18 years or older
- Able and willing to provide informed consent
- Able to tolerate compression therapy for Venus Leg Ulcer
- Must be able to be compliant with compression therapy
Exclusion Criteria:
- Known sensitivities or allergies to components of the AQUACEL® Ag+ Extra™ or Cutimed® Sorbact®
- Continued use of petroleum gel/ creams/ oil-based products
- Active treatment for cancer or completed within the last 3 months
- Documented severe malnutrition
- Malignant wounds
- Systemic infection actively treated with antibiotics
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: AQUACEL® Ag+ Extra™
AQUACEL® Ag+ Extra™ is approved, needle-bonded nonwoven fabric layered and stitch-bonded wound dressing
|
Wound treatment with AQUACEL® Ag+ Extra™ dressing
|
Active Comparator: Cutimed® Sorbact®
Cutimed® Sorbact® is approved, bacterial and fungi binding wound dressing
|
Wound treatment with Cutimed® Sorbact® dressing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effectiveness of AQUACEL® Ag+ Extra™ and Cutimed® Sorbact® on wound management
Time Frame: Up to 12 weeks
|
Complete wound closure as defined by 100% epithelialisation of the wound surface (Gould 2019)
|
Up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wound healing assessment
Time Frame: Up to 4 weeks
|
Percent change in study wound area
|
Up to 4 weeks
|
Wound progress assessment
Time Frame: Up to 4 weeks
|
Satisfactory clinical progress defined as 40% reduction in study wound area
|
Up to 4 weeks
|
Wound change assessment
Time Frame: Up to 12 weeks
|
Percent change in target wound area
|
Up to 12 weeks
|
Safety assesment
Time Frame: Up to 12 weeks
|
Summary of the incidence of adverse events (AEs), device-related AEs and serious device-related AEs
|
Up to 12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain assessment
Time Frame: Up to 12 weeks
|
Numeric Rating Scale from 0 to 10
|
Up to 12 weeks
|
Quality of Life assesment
Time Frame: Up to 12 weeks
|
Wound-QoL-14 global score
|
Up to 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Catarina Saavedra, MD, Convatec Colombia Clinic
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 5, 2022
Primary Completion (Actual)
February 14, 2024
Study Completion (Actual)
February 14, 2024
Study Registration Dates
First Submitted
May 10, 2023
First Submitted That Met QC Criteria
May 26, 2023
First Posted (Actual)
June 7, 2023
Study Record Updates
Last Update Posted (Actual)
March 20, 2024
Last Update Submitted That Met QC Criteria
March 19, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Endocrine System Diseases
- Diabetic Angiopathies
- Skin Ulcer
- Diabetes Complications
- Diabetes Mellitus
- Diabetic Neuropathies
- Varicose Veins
- Foot Ulcer
- Diabetic Foot
- Ulcer
- Leg Ulcer
- Varicose Ulcer
- Gastrointestinal Agents
- Laxatives
- Carboxymethylcellulose Sodium
Other Study ID Numbers
- WC-22-435
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot
-
University of PadovaUnknownDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Deformities FootItaly
-
Johns Hopkins UniversityWithdrawnDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Mixed | Vascular Ulcer (Arterial or Venous Including Diabetic Ulcers Not Located on the Foot)
-
Integra LifeSciences CorporationMayo Clinic; Temple University; Samuel Merritt University; New York College of... and other collaboratorsCompletedFoot Ulcers, DiabeticUnited States
-
Community Pharmacology Services LtdKeneric HealthcareNot yet recruitingDiabetic Foot Ulcer | Diabetic Foot Ulcer Neuropathic | Diabetic Foot Ulcer Ischemic
-
Exciton Technologies Inc.CompletedDiabetic Foot Ulcer | Diabetic Foot Infection | Non-healing Diabetic Foot UlcerCanada
-
Corporacion Parc TauliCompletedDiabetic Foot Ulcer | Diabetic Foot Ulcer NeuropathicPakistan
-
University of the PunjabHigher Education Commission (Pakistan); Centre of Excellence in Molecular Biology... and other collaboratorsRecruitingDiabetes Mellitus | Diabetic Foot | Foot Ulcer | Diabetes Complications | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Foot Ulcer Due to Type 1 Diabetes Mellitus | Foot Ulcer Due to Type 2 Diabetes Mellitus | Chronic Diabetic Ulcer of Left Foot | Chronic Diabetic Foot...Pakistan
-
University of MinnesotaRecruitingDiabetes Mellitus | Foot Ulcer | Ulcer | Diabetic Foot Ulcer | Foot Ulcer, Diabetic | Ulcer Foot | Ulcer, Leg | Ankle UlcerUnited States
-
HealthpointCompletedDiabetic Foot Ulcers | Diabetic Foot WoundsUnited States, Canada
-
HealthpointCompleted
Clinical Trials on AQUACEL® Ag+ Extra™
-
ConvaTec Inc.CompletedLeg UlcerUnited Kingdom, Germany, Netherlands, Poland
-
Dr Angela OatesConvaTec Inc.CompletedDiabetes | Chronic Foot WoundsUnited Kingdom
-
Molnlycke Health Care ABCompleted
-
ConvaTec Inc.CompletedLeg UlcersUnited Kingdom
-
Kansas City Heart Rhythm InstituteCompletedWounds and Injuries | InfectionsUnited States
-
Golden Jubilee National HospitalConvaTec Inc.Withdrawn
-
ConvaTec Inc.Bristol-Myers SquibbCompletedSplit-Thickness Donor Sites.United States
-
ConvaTec Inc.CompletedLeg UlcerDenmark, France, Germany, Poland, United Kingdom
-
National Taiwan University HospitalUnknownUlcer | Head and Neck Cancer | Head and Neck Neoplasms | WoundsTaiwan
-
Coloplast A/SCompletedDiabetic Foot Ulcer | Venous Leg UlcerUnited Kingdom